Cenerimod in Systemic Lupus Erythematosus

Phase 2, randomised, double-blind trial of cenerimod in systemic lupus erythematosus (SLE) (5 arms), sponsored by Viatris. Primary endpoints: Change in Total Lymphocyte Count From Baseline to End-of-treatment (EOT) at 12 weeks and Change in Total Lymphocyte Count From Baseline to Each Post-baseline Assessment at 12 weeks. Started Jun 2015; status: completed.